Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Sell
32
RGNX Quote, Financials, Valuation and Earnings
Last price:
$9.16
Seasonality move
:
1.72%
Day range:
$8.76 - $9.34
52-week range:
$5.04 - $15.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.01x
P/B ratio:
1.70x
Volume:
798K
Avg. volume:
1.3M
1-year change:
-26.19%
Market cap:
$465M
Revenue:
$83.3M
EPS (TTM):
-$3.11
Analysts' Opinion
-
Consensus RatingRegenxbio has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.75, Regenxbio has an estimated upside of 242.5% from its current price of $9.16.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing -40.24% downside risk from its current price of $9.16.
Fair Value
-
According to the consensus of 7 analysts, Regenxbio has 242.5% upside to fair value with a price target of $31.75 per share.
RGNX vs. S&P 500
-
Over the past 5 trading days, Regenxbio has underperformed the S&P 500 by -3.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Regenxbio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regenxbio has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Regenxbio reported revenues of $89M.
Earnings Growth
-
Regenxbio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Regenxbio reported earnings per share of $0.12.
Enterprise value:
197.1M
EV / Invested capital:
0.72x
Price / LTM sales:
3.01x
EV / EBIT:
--
EV / Revenue:
1.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$124M
Return On Assets:
-29.48%
Net Income Margin (TTM):
-100.62%
Return On Equity:
-50.09%
Return On Invested Capital:
-50.09%
Operating Margin:
13.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $109.6M | $86.7M | $156.7M | $15.6M | $89M | |
| Gross Profit | $66.7M | $49.3M | $124M | $11.3M | $85.6M | |
| Operating Income | -$257.5M | -$263.7M | -$157.4M | -$61.8M | $12.1M | |
| EBITDA | -$235.9M | -$236.9M | -$122.4M | -$57.2M | $18.6M | |
| Diluted EPS | -$6.24 | -$5.87 | -$3.11 | -$1.38 | $0.12 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $498.6M | $446.9M | $389.2M | $395.4M | $313.2M | |
| Total Assets | $879.4M | $1B | $747.8M | $629.2M | $490.9M | |
| Current Liabilities | $84M | $119.9M | $112.3M | $110.2M | $106.7M | |
| Total Liabilities | $324.9M | $335.7M | $282.7M | $238.5M | $216.7M | |
| Total Equity | $554.5M | $689.7M | $465.1M | $390.7M | $274.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$232.5M | -$192.9M | -$84M | -$55.5M | $33.6M | |
| Cash From Investing | $141.8M | $141M | $135M | $13.2M | $44.7M | |
| Cash From Financing | -$31M | $94.8M | -$33.8M | $120.7M | -$5.8M | |
| Free Cash Flow | -$257.1M | -$198.6M | -$86.9M | -$56M | $32.6M | |
RGNX
Sector
Market Cap
$465M
$32.3M
Price % of 52-Week High
60.35%
46.89%
Dividend Yield
0%
0%
Shareholder Yield
-0.15%
-0.66%
1-Year Price Total Return
-29.13%
-37.62%
Beta (5-Year)
1.089
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.52
200-day SMA
Buy
Level
$8.87
Bollinger Bands (100)
Buy
Level
6.62 - 9.22
Chaikin Money Flow
Buy
Level
5M
20-day SMA
Sell
Level
$9.56
Relative Strength Index (RSI14)
Sell
Level
49.44
ADX Line
Sell
Level
16.3
Williams %R
Neutral
Level
-56.7288
50-day SMA
Buy
Level
$8.45
MACD (12, 26)
Buy
Level
0.28
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
26.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.5764)
Sell
CA Score
(Annual)
Level (-2.035)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (3.1097)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Stock Forecast FAQ
In the current month, RGNX has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RGNX average analyst price target in the past 3 months is $31.75.
-
Where Will Regenxbio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regenxbio share price will rise to $31.75 per share over the next 12 months.
-
What Do Analysts Say About Regenxbio?
Analysts are divided on their view about Regenxbio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regenxbio is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Regenxbio's Price Target?
The price target for Regenxbio over the next 1-year time period is forecast to be $31.75 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RGNX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regenxbio is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RGNX?
You can purchase shares of Regenxbio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regenxbio shares.
-
What Is The Regenxbio Share Price Today?
Regenxbio was last trading at $9.16 per share. This represents the most recent stock quote for Regenxbio. Yesterday, Regenxbio closed at $9.16 per share.
-
How To Buy Regenxbio Stock Online?
In order to purchase Regenxbio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Where Will AST SpaceMobile Be In 5 Years?
Ever tried to send a text from the Nevada desert…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is down 89.92% over the past day.
Sell
16
VEON alert for Jun 17
VEON [VEON] is up 4.61% over the past day.
Buy
64
INOD alert for Jun 17
Innodata [INOD] is up 13.78% over the past day.
